Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

The Search for Animal Alternatives

May 18, 2010 10:57 am | by Alan Dove, Contributing Editor | Articles | Comments

New assays based on nanotechnology and stem cell science promise to reduce the need for laboratory animals while increasing the success rate of new leads.


Unlocking hESC Success

May 18, 2010 10:00 am | by Ted Agres, Contributing Editor | Articles | Comments

Industry-Academia collaborations may pay off with hESC-based drug screening advances.


Ricerca Appoints New Vice President

May 18, 2010 8:06 am | News | Comments

Ricerca Biosciences, a uniquely integrated preclinical contract research organization providing services to the biopharmaceutical industry, announced that Michael E. Placke, PhD, DABT, will join Ricerca as senior vice president and general manager at their Concord, Ohio, facility.


EMCCD Camera

May 18, 2010 7:14 am | Product Releases | Comments

With the help of a highly sensitive Andor iXon+ EMCCD camera, US researchers have developed a super-resolution, 3D imaging technique that can resolve single fluorescent molecules with greater than 10 times more precision than conventional optical microscopy.


Thermal Cycler

May 18, 2010 7:09 am | Product Releases | Comments

Fluidigm Corporation introduced its FC1 Cycler designed to reduce the thermal cycling time by a factor of three when compared with the company’s current products.


ADDF Announces Biomarker Discovery Research Awards

May 18, 2010 7:00 am | News | Comments

The Alzheimer's Drug Discovery Foundation (ADDF) and the Lewy Body Dementia Association (LBDA) announced today the recipient of their first partnership research award through the Lewy Body Dementia Biomarker Research Program.


NORD To Honor Eight Over Rare Diseases

May 18, 2010 6:34 am | News | Comments

The National Organization for Rare Disorders (NORD) will honor two trailblazing scientists, a pioneering patient organization, and five companies that have brought innovative new treatments to market for rare diseases at the 2010 NORD Partners in Progress Gala.


Radiotherapy Extends Life In Certain Brain Cancer Patients

May 18, 2010 6:19 am | News | Comments

Patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives, according to researchers at Thomas Jefferson University.


Caffeine Slows Progression of Alzheimer's

May 18, 2010 6:15 am | News | Comments

Although caffeine is the most widely consumed psychoactive drug worldwide, its potential beneficial effect for maintenance of proper brain functioning has only recently begun to be adequately appreciated.


Vaginal Gel May Help in Fight Against AIDS

May 18, 2010 6:04 am | by Lauran Neergaard | News | Comments

Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings.


Jury Finds Novartis Guilty of Discrimination

May 18, 2010 6:00 am | by Larry Neumeister | News | Comments

A jury decided that the drug company Novartis engaged in a pattern of discrimination against women, paying them less than men, cheating them of promotions and treating pregnant women unfavorably.


Electron Microscopy for Therapeutics

May 17, 2010 12:31 pm | by Mike May, Contributing Editor | Articles | Comments

Advances in electron microscopy reveal new opportunities in drug discovery and development.


Read the Label

May 17, 2010 12:19 pm | by Rita C. Peters, Editorial Director | Articles | Comments

In this issue’s cover story, we address the search for alternatives to animal testing for drug safety. Using animal models to test the safety of drugs for humans has long been a controversial topic.


Clinipace to Manage Vaccigen’s Global Phase 3b Clinical Trial

May 17, 2010 12:03 pm | News | Comments

Vaccinogen selected Clinipace Worldwide to manage a Phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.


CEDRA Corporation Names Anthony Busa CEO

May 17, 2010 11:36 am | News | Comments

CEDRA Corporation (Austin, Tex.), a division of Worldwide Clinical Trials (WCT) and a provider of Phase 1 clinical research and bioanalytical services, announced that Anthony G. Busa, Jr., has been named chief executive officer.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.